Wu J, Liu SZ, Dong SS, Dong XP, Zhang WL, Lu M, Li. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: A phase I-II randomized trial. Vaccine. 2010 Jul 15. Abstract submitted by kickingbird at Jul, 25, 2010 from Vaccine. 2010 Jul 15 OBJECTIVE: Highly pathogenic avian influenza A virus H5N1 has the potential to cause a pandemic. Many prototype pandemic influenza A (H5N1) vaccines had been developed and well evaluated in adults in recent ... WU J, Li W, Wang HQ, Chen JT, et al.. A Rapid Immune Response to 2009 Influenza A(H1N1) Vaccines in Adults: A Randomized, Double-Blind, Controlled Trial. J Infect Dis. 2010 Jul 15. Abstract submitted by kickingbird at Jul, 25, 2010 from J Infect Dis. 2010 Jul 15 A double-blind, randomized, controlled trial involving 706 adults was conducted to evaluate the immunogenicity and safety of different dosages of whole-virion or split-virion H1N1 influenza vaccines with ... Mueller SN, Langley WA, Li G, García-Sastre A, Web. Qualitatively Different Memory CD8+ T Cells Are Generated after Lymphocytic Choriomeningitis Virus and Influenza Virus Infections. J Immunol. 2010 Jul 16.. Abstract submitted by kickingbird at Jul, 25, 2010 from J Immunol. 2010 Jul 16. Viral infections often induce robust T cell responses that are long-lived and protective. However, it is unclear to what degree systemic versus mucosal infection influences the generation of effector and ... SMEE DF, Hurst BL, Wong MH, Tarbet EB, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010 Jul 13. Abstract submitted by kickingbird at Jul, 25, 2010 from Antiviral Res. 2010 Jul 13 Oseltamivir and peramivir are being considered for combination treatment of serious influenza virus infections in humans. Both compounds are influenza virus neuraminidase inhibitors, and since peramivir ... SUNDARARAJAN A, Ganapathy R, Huan L, Dunlap JR, et. Influenza virus variation in susceptibility to inactivation by pomegranate polyphenols is determined by envelope glycoproteins. Antiviral Res. 2010 Jul 14. Abstract submitted by kickingbird at Jul, 25, 2010 from Antiviral Res. 2010 Jul 14 Pomegranates have high levels of polyphenols (PPs) and may be a rich source of compounds with antiviral activity. We evaluated the direct anti-influenza activity of three commercially available pomegranate ... | |